MEDCL.PA
Price:
$29.06
Market Cap:
$1.04B
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, prese...[Read more]
Industry
Biotechnology
IPO Date
2018-10-08
Stock Exchange
PAR
Ticker
MEDCL.PA
According to MedinCell S.A.’s latest financial reports and current stock price. The company's current ROE is 226.98%. This represents a change of -330.86% compared to the average of -98.32% of the last 4 quarters.
The mean historical ROE of MedinCell S.A. over the last ten years is -73.08%. The current 226.98% ROE has changed -410.59% with respect to the historical average. Over the past ten years (40 quarters), MEDCL.PA's ROE was at its highest in in the September 2021 quarter at 722.24%. The ROE was at its lowest in in the March 2026 quarter at -496.38%.
Average
-73.08%
Median
78.46%
Minimum
-1021.12%
Maximum
185.52%
Discovering the peaks and valleys of MedinCell S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 204.42%
Maximum Annual ROE = 185.52%
Minimum Annual Increase = -1006.42%
Minimum Annual ROE = -1021.12%
| Year | ROE | Change |
|---|---|---|
| 2026 | -1021.12% | -1006.42% |
| 2025 | 112.65% | 83.68% |
| 2024 | 61.33% | -18.96% |
| 2023 | 75.68% | -59.20% |
| 2022 | 185.52% | -186.97% |
| 2021 | -213.32% | -242.35% |
| 2020 | 149.86% | -147.52% |
| 2019 | -315.35% | -488.23% |
| 2018 | 81.23% | -46.81% |
| 2017 | 152.70% | 204.42% |
The current ROE of MedinCell S.A. (MEDCL.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-282.38%
5-year avg
-117.19%
10-year avg
-73.08%
MedinCell S.A.’s ROE is less than Crossject S.A. (1.48%), less than Adocia S.A. (1.03%),
| Company | ROE | Market cap |
|---|---|---|
| 1.48% | $79.12M | |
| 1.03% | $41.10M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MedinCell S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MedinCell S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is MedinCell S.A.'s ROE?
How is the ROE calculated for MedinCell S.A. (MEDCL.PA)?
What is the highest ROE for MedinCell S.A. (MEDCL.PA)?
What is the 3-year average ROE for MedinCell S.A. (MEDCL.PA)?
What is the 5-year average ROE for MedinCell S.A. (MEDCL.PA)?
How does the current ROE for MedinCell S.A. (MEDCL.PA) compare to its historical average?